Ergoteles’s CorMedix CRMD Stock Holding History

Ergoteles’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-159,063	Closed	-$450K	–	1523
2022 Q3	$450K	Sell	159,063 -24,237	-13%	-$101K	0.02%	802
2022 Q2	$737K	Buy	+183,300	New	+$681K	0.02%	672

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Ergoteles's CRMD Position: Q4 2022 in Review

Ergoteles sold out of CorMedix (CRMD) in Q4 2022, closing a stake of 159,063 shares — an estimated $450K sold.

Ergoteles first reported a position in CRMD in Q2 2022 and held it in 2 quarters. The position peaked at $737K in Q2 2022. 66 funds tracked by Wall St. Rank hold CRMD as of Q4 2022.

Ergoteles reported no remaining CorMedix position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 159,063 CorMedix shares in Q4 2022, an estimated $450K.
Ergoteles first reported a position in CorMedix in Q2 2022 and held it in 2 quarters.
Ergoteles's CorMedix position peaked at $737K in Q2 2022.
66 funds tracked by Wall St. Rank held CorMedix as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.